Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
Peter Q. Huang, Brant C. Boren, Sayee G. Hegde, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 17, pp. 13004-13024
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Targeted therapy for osteosarcoma: a review
Shizhe Li, He Zhang, Jinxin Liu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6785-6797
Closed Access | Times Cited: 46
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 16
Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
Amirali B. Bukhari, Gordon K. Chan, Armin M. Gamper
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 40
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
Siqing Fu, Shuyang Yao, Yuan Yuan, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 9, pp. 1725-1734
Open Access | Times Cited: 38
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders
Vidya Jyothi Alli, Pawan Kumar Yadav, V. Suresh, et al.
ACS Omega (2023) Vol. 8, Iss. 23, pp. 20196-20233
Open Access | Times Cited: 16
Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing’s sarcoma cells
Judy Ziener, Julián Henao‐Restrepo, Johanna Leonhardi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids
Joel L. Syphers, Josephine A. Wright, Shen Liu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy
Sajjad Vakili‐Samiani, Omid Joodi Khanghah, Elham Gholipour, et al.
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis (2022) Vol. 824, pp. 111776-111776
Closed Access | Times Cited: 22
Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression
Satenig Guler, Maria C. DiPoto, Alejandro Crespo, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 5, pp. 566-576
Open Access | Times Cited: 11
Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 6, pp. 101578-101578
Open Access | Times Cited: 4
Telomere-related DNA damage response pathways in cancer therapy: prospective targets
Liting Gu, Mingdi Liu, Yuning Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
AutoDesigner - Core Design, a De Novo Design Algorithm for Chemical Scaffolds: Application to the Design and Synthesis of Novel Selective Wee1 Inhibitors
Pieter H. Bos, Fabio Ranalli, E. A. Flood, et al.
(2024)
Open Access | Times Cited: 4
Targeting WEE1 Kinase in Gynecological Malignancies
Wenhao Zhang, Qingli Li, Rutie Yin
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2449-2460
Open Access | Times Cited: 4
Targeting the DNA damage response in cancer
Guffanti Federica, Chiappa Michela, Giovanna Damia
MedComm (2024) Vol. 5, Iss. 11
Open Access | Times Cited: 4
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
Daehwan Kim, Heekyung Chung, Wen Liu, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
The expanding role of WEE1
Siang‐Boon Koh
Cellular Signalling (2022) Vol. 94, pp. 110310-110310
Closed Access | Times Cited: 18
Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1
Xuesen Qi, Guozhen Li, Jiahai Liu, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 6, pp. 3010-3018
Closed Access | Times Cited: 10
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors
Chi Zhang, Ke Peng, Qing Liu, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104233-104233
Closed Access | Times Cited: 8
The Adaptive Mechanisms and Checkpoint Responses to a Stressed DNA Replication Fork
Joanne Saldanha, Julie Rageul, Jinal A Patel, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10488-10488
Open Access | Times Cited: 7
Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy
Yong Wang, Xu Chunyue, Yiqing Jiang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 9927-9949
Closed Access | Times Cited: 2
AutoDesigner - Core Design, a De Novo Design Algorithm for Chemical Scaffolds: Application to the Design and Synthesis of Novel Selective Wee1 Inhibitors
Pieter H. Bos, Fabio Ranalli, E. A. Flood, et al.
(2024)
Open Access | Times Cited: 2
The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy
Emma Melia, Jason L. Parsons
Cancers (2024) Vol. 16, Iss. 17, pp. 3016-3016
Open Access | Times Cited: 2
CELL CYCLE DYSREGULATION IN CANCER
Antonino Glaviano, Samarendra Kumar Singh, E. Hui Clarissa Lee, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 2, pp. 100030-100030
Closed Access | Times Cited: 2
Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer
Shaobin Wang, Chao Wang, Tingting Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 1, pp. 420-432
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top